Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases

Journal of the American College of Cardiology

Volumn 71, Issue 5, 2018, Pages 564-574

  Kishore, Sandeep P ^a   Blank, Evan ^a   Heller, David J ^a   Patel, Amisha ^b   Peters, Alexander ^c,d,e   Price, Matthew ^f   Vidula, Mahesh ^g   Fuster, Valentin ^a   Onuma, Oyere ^h   Huffman, Mark D ⁱ   Vedanthan, Rajesh ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f Independent Consultant   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cardiovascular disease; essential medicines; NCDs; WHO Essential Medicines List

Indexed keywords

APIXABAN; ATENOLOL; BISOPROLOL; CLOPIDOGREL; DABIGATRAN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; RIVAROXABAN; SIMVASTATIN; SPIRONOLACTONE; ESSENTIAL DRUG;

ACUTE CORONARY SYNDROME; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EVIDENCE BASED PRACTICE; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART PROTECTION; HUMAN; HYPERTENSION; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; TREATMENT INDICATION; WORLD HEALTH ORGANIZATION; PUBLICATION;

CARDIOVASCULAR DISEASES; DRUGS, ESSENTIAL; FORMULARIES AS TOPIC; HUMANS; WORLD HEALTH ORGANIZATION;

EID: 85044870466     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.11.056     Document Type: Review

References (76)

1. Wang, H., Naghavi, M., Allen, C., et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1459–1544.
2. World Health Organization. Global Hearts Initiative: working together to beat cardiovascular diseases. Available at: http://www.who.int/cardiovascular_diseases/global-hearts/GHI_Brochure.pdf?ua=1. Accessed January 3, 2017.
3. Perel, P., Avezum, A., Huffman, M., et al. Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation Roadmap for secondary prevention of cardiovascular disease. Glob Heart 10 (2015), 99–110.
4. Cameron, A., Roubos, I., Ewen, M., et al. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 89 (2011), 412–421.
5. Khatib, R., McKee, M., Shannon, H., et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387 (2016), 61–69.
6. Bazargani, Y.T., Ewen, M., de Boer, A., Leufkens, H.G.M., Mantel-Teeuwisse, A.K., Essential medicines are more available than other medicines around the globe. PLOS ONE, 9, 2014, e87576.
7. World Health Organization. Essential medicines and health products. Available at: http://www.who.int/medicines/services/essmedicines_def/en/. Accessed January 3, 2017.
8. World Health Organization. WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers. May 8, 2015. Available at: http://www.who.int/mediacentre/news/releases/2015/new-essential-medicines-list/en/. Accessed January 3, 2017.
9. World Health Organization. Towards access 2030: WHO essential medicines and health products strategic framework 2016–2030. Available at: http://www.who.int/medicines/publications/Towards_Access_2030_Final.pdf?ua=1. Accessed June 13, 2017.
10. Hoen, E., Berger, J., Calmy, A., Moon, S., Driving a decade of change: HIV/AIDS, patents, and access to medicines for all. J Int AIDS Soc, 14, 2011, 15.
11. Anderson, J.L., Evolution of the ACC/AHA clinical practice guidelines in perspective: guiding the guidelines. J Am Coll Cardiol 65 (2015), 2735–2738.
12. Jacobs, A.K., Anderson, J.L., Halperin, J.L., The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), 1373–1384.
13. World Health Organization. Members of the 20th Expert Committee on the Selection and Use of Essential Medicines. Available at: http://www.who.int/selection_medicines/committees/expert/20/experts/members-committee/en/. Accessed January 3, 2017.
14. Ounpuu, S., Negassa, A., Yusuf, S., INTER-HEART: a global study of risk factors for acute myocardial infarction. Am Heart J 141 (2001), 711–721.
15. Taylor, F., Huffman, M.D., Macedo, A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 1, 2013, CD004816.
16. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
17. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
18. CNN Money. Zocor and Zoloft face patent expiration. Available at: http://money.cnn.com/2006/06/15/news/companies/zoloft_zocor/index.htm. Accessed December 16, 2017.
19. Management Sciences for Health. International drug price indicator guide 2007. Available at: http://mshpriceguide.org/wp-content/uploads/2016/06/MSH-International-Drug-Price-Indicator-Guide-2007.pdf. Accessed June 21, 2017.
20. World Health Organization. Package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Available at: http://www.who.int/nmh/publications/essential_ncd_interventions_lr_settings.pdf?ua=1. Accessed January 3, 2017.
21. Salpeter, S., Ormiston, T., Salpeter, E., Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 4, 2005, CD003566.
22. Dickstein, K., Cohen-Solal, A., Filippatos, G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10 (2008), 933–989.
23. Jessup, M., Abraham, W.T., Casey, D.E., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53 (2009), 1343–1382.
24. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
25. Heart Failure Society of America. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16 (2010), 475–539.
26. Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
27. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), e78–e140.
28. Sabatine, M.S., Cannon, C.P., Gibson, C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005), 1179–1189.
29. Yusuf, S., Zhao, F., Mehta, S.F., Chrolavicius, S., Tognoni, G., Fox, K.K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
30. Gao, R., Current status of percutaneous coronary intervention in China. Heart 96 (2010), 415–418.
31. Hun, Y., Current status and development of percutaneous coronary intervention in China. J Zhejiang Univ Sci B 11 (2010), 631–633.
32. Ramakrishnan, S., Mishra, S., Chakraborty, R., Chandra, K.S., Mardikar, H.M., The report on the Indian coronary intervention data for the year 2011—National Interventional Council. Indian Heart J 65 (2013), 518–521.
33. Patel, A., Vidula, M., Kishore, S.P., Vedanthan, R., Huffman, M.D., Building the case for clopidogrel as a World Health Organization essential medicine. Circ Cardiovasc Qual Outcomes 8 (2015), 447–451.
34. de Vreede, J.J., Gorgels, A.P., Verstraaten, G.M., Vermeer, F., Dassen, W.R., Wellens, H.J., Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol 18 (1991), 698–706.
35. Flynn, A., Moscucci, M., Share, D., et al. Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Arch Intern Med 170 (2010), 1842–1849.
36. Gillum, R.F., Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol 23 (1994), 1273–1277.
37. Krumholz, H.M., Normand, S.L., Wang, Y., Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999-2011. Circulation 130 (2014), 966–975.
38. Karthikeyan, G., Xavier, D., Prabhakaran, D., Pais, P., Perspectives on the management of coronary artery disease in India. Heart 93 (2007), 1334–1338.
39. Yusuf, S., Islam, S., Chow, C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378 (2011), 1231–1243.
40. Kaul, U., Bhatia, V., Perspective on coronary interventions and cardiac surgeries in India. Indian J Med Res 132 (2010), 543–548.
41. Yusuf, S., Teo, K.K., Pogue, J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
42. Yusuf, S., Teo, K., Anderson, C., et al., for the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008), 1174–1183.
43. World Health Organization. WHO model list of essential medicines: 16th list (updated) March 2010. Available at: http://apps.who.int/iris/bitstream/10665/70643/1/a95060_eng.pdf. Accessed June 13, 2017.
44. Israili, Z.H., Hall, W.D., Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117 (1992), 234–242.
45. Woo, K.S., Nicholls, M.G., High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 40 (1995), 141–144.
46. Brown, N.J., Ray, W.A., Snowden, M., Griffin, M.R., Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther, 60, 1996, 8.
47. Management Sciences for Health. International drug price indicator guide, 2014 edition. Available at: http://apps.who.int/medicinedocs/documents/s21982en/s21982en.pdf. Accessed December 19, 2016.
48. Li, E.C., Heran, B.S., Wright, J.M., Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev, 8, 2014, CD009096.
49. Bangalore, S., Fakheri, R., Toklu, B., Ogedegbe, G., Weintraub, H., Messerli, F.H., Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 91 (2016), 51–60.
50. Ricci, F., Di Castelnuovo, A., Savarese, G., Filardi, P.P., De Caterina, R., ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure—a network meta-analysis. Int J Cardiol 217 (2016), 128–134.
51. Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129 (2014), 837–847.
52. Kansal, A.R., Zheng, Y., Pokora, T., Sorensen, S.V., Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol 26 (2013), 225–237.
53. Neumann I, Schünemann HJ. Novel oral anticoagulants—addition—EML. 2014. Available at: http://www.who.int/selection_medicines/committees/expert/20/applications/NOACs/en/. Accessed June 25, 2017.
54. World Health Organ Expert Committee. The selection and use of essential medicines. Report of the WHO Expert Committee, 2015. Available at: http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946_eng.pdf?ua=1. Accessed June 21, 2017.
55. Canadian Agency for Drugs and Technologies in Health. CADTH therapeutic review recommendations: new oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation. June 2012. Available at: https://www.cadth.ca/media/pdf/tr0002_New-Oral-Anticoagulants_rec_e.pdf. Accessed August 18, 2017.
56. Lim, S.S., Vos, T., Flaxman, A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2224–2260.
57. Paz, M.A., de-La-Sierra, A., Sáez, M., et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine, 95, 2016, e4071.
58. Chobanian, A.V., Bakris, G.L., Black, H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
59. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31 (2013), 1281–1357.
60. Wald, D.S., Law, M., Morris, J.K., Bestwick, J.P., Wald, N.J., Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122 (2009), 290–300.
61. Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
62. Jarari, N., Rao, N., Peela, J.R., et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens, 22, 2016, 7.
63. World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children). Available at: http://www.who.int/medicines/publications/essentialmedicines/EML_2017_EC21_Unedited_Full_Report.pdf?ua=1. Accessed June 13, 2017.
64. Huffman, M.D., Yusuf, S., Polypills: essential medicines for cardiovascular disease secondary prevention?. J Am Coll Cardiol 63 (2014), 1368–1370.
65. Huffman MD, Perel P, Castellano JM, et al. Essential medicines selection. Aspirin + statin + antihypertensive—addition—EML. 2014. Available at: http://www.who.int/selection_medicines/committees/expert/20/applications/aspirin_statin_antihyper_Ad/en/. Accessed June 21, 2017.
66. World Health Organization. Essential medicines selection. Aspirin + atorvastatin + ramipril (polypill)—EML. Available at: http://www.who.int/selection_medicines/committees/expert/21/applications/aspirin_atorvastatin_ramipril_ad/en/. Accessed June 13, 2017.
67. Bahiru, E., de Cates, A.N., Farr, M.R.B., et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev, 3, 2017, CD009868.
68. World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee, 2015 (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children). Available at: http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946_eng.pdf?ua=1. Accessed June 25, 2017.
69. World Health Organization. WHO takes major steps to make HIV treatment accessible. April 22, 2002. Available at: http://www.who.int/mediacentre/news/releases/release28/en/. Accessed January 3, 2017.
70. World Health Organization. Cardiovascular disease. Global Hearts initiative. Available at: http://www.who.int/cardiovascular_diseases/global-hearts/en/. Accessed December 19, 2016.
71. Owalabi, M., Olowoyo, P., Miranda, J.J., et al. Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High Income Countries: A Systematic Review. Hypertension 68 (2016), 1328–1337.
72. Perel, P., Bianco, E., Poulter, N., et al. Adapting the World Heart Federation Roadmaps at the national level: next steps and conclusions. Glob Heart 10 (2015), 135–136.
73. McGettigan, P., Henry, D., Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLOS Med, 10, 2013, e1001388.
74. Reddy, K.S., Roy, A., Cardiovascular risk of NSAIDs: time to translate knowledge into practice. PLOS Med, 10, 2013, e1001389.
75. Wirtz, V.J., Kaplan, W.A., Kwan, G.F., Laing, R.O., Access to medications for cardiovascular diseases in low- and middle-income countries. Circulation 133 (2016), 2076–2085.
76. IMS Institute for Healthcare Informatics. Understanding the role and use of essential medicines lists. 2015. Available at: http://apps.who.int/medicinedocs/documents/s21980en/s21980en.pdf. Accessed October 26, 2017.